Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
GUTS Stock Forecast 2026-2027
$0.85
Current Price
$144.37M
Market Cap
Buy 6
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to GUTS Price Targets
+836.4%
To High Target of $8.00
+497.0%
To Median Target of $5.10
+134.1%
To Low Target of $2.00
GUTS Price Momentum
+7.6%
1 Week Change
0.0%
1 Month Change
-52.5%
1 Year Change
-61.4%
Year-to-Date Change
-65.1%
From 52W High of $2.45
+126.6%
From 52W Low of $0.38
📊 TOP ANALYST CALLS
Did GUTS Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Fractyl Health is one of their latest high-conviction picks.
Latest GUTS Stock Price Targets & Analyst Predictions
Based on our analysis of 2 Wall Street analysts, GUTS has a bullish consensus with a median price target of $5.10 (ranging from $2.00 to $8.00). The overall analyst rating is Strong Buy (9.4/10). Currently trading at $0.85, the median forecast implies a 497.0% upside. This outlook is supported by 6 Buy, 1 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
GUTS Analyst Ratings
6
Buy
1
Hold
0
Sell
GUTS Price Target Range
Low
$2.00
Average
$5.10
High
$8.00
Current: $0.85
Latest GUTS Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for GUTS.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jul 1, 2026 | Craig-Hallum | Chase Knickerbocker | Buy | Initiates | $4.00 |
| Jun 4, 2026 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Apr 24, 2026 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Mar 26, 2026 | Canaccord Genuity | Buy | Maintains | $N/A | |
| Jan 30, 2026 | Morgan Stanley | Equal-Weight | Downgrade | $N/A | |
| Dec 2, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Nov 21, 2025 | Canaccord Genuity | Buy | Maintains | $N/A | |
| Sep 26, 2025 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Sep 15, 2025 | HC Wainwright & Co. | Buy | Initiates | $N/A | |
| Aug 28, 2025 | Ladenburg Thalmann | Buy | Initiates | $N/A | |
| Aug 14, 2025 | Canaccord Genuity | Buy | Maintains | $N/A | |
| Apr 15, 2025 | Canaccord Genuity | Buy | Initiates | $N/A | |
| Feb 3, 2025 | Morgan Stanley | Overweight | Maintains | $N/A | |
| Feb 28, 2024 | Evercore ISI Group | Outperform | Initiates | $N/A | |
| Feb 27, 2024 | Morgan Stanley | Overweight | Initiates | $N/A |
Fractyl Health Inc. (GUTS) Competitors
The following stocks are similar to Fractyl Health based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
GUTS
Fractyl Health
mkt cap
125.76M
Fractyl Health Inc. (GUTS) Financial Data
Fractyl Health Inc. has a market capitalization of $144.37M with a P/E ratio of -0.9x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -778.3%.
Valuation Metrics
Market Cap
$144.37M
Enterprise Value
$142.02M
P/E Ratio
-0.9x
PEG Ratio
0.0x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+46.6%
Current Ratio
4.3x
Debt/Equity
284.5x
ROE
-778.3%
ROA
-63.6%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Fractyl Health Inc. (GUTS) Business Model
About Fractyl Health Inc.
What They Do
Develops treatments for chronic metabolic diseases.
Business Model
Fractyl Health Inc. focuses on innovative procedural therapies to treat chronic metabolic conditions, particularly type 2 diabetes, by targeting their root causes. The company generates revenue through its research and clinical trials, aiming to bring new therapies to the market that improve patient outcomes and reduce healthcare costs.
Additional Information
The company is positioned as a leader in gastrointestinal treatment and metabolic disease management, addressing the global epidemic of metabolic diseases. Its commitment to advancing medical science is demonstrated through extensive research efforts and clinical trials.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
100
CEO
Dr. Harith Rajagopalan M.D., Ph.D.
Country
United States
IPO Year
N/A
Website
fractyl.comFractyl Health Inc. (GUTS) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Fractyl Health Stock Up on Encouraging One-Year Revita Study Results
GUTS' shares surge after Revita patients retain up to 84% of GLP-1-induced weight loss in a year, compared with 46% for sham patients.
Jul 16, 2026
By Zacks Equity Research
Analyst Blog
Latest News
Quick Summary
Fractyl Health (NASDAQ: GUTS) reported positive one-year data from its REMAIN-1 study, showing its Revita procedure helps patients retain more weight loss after stopping GLP-1 therapy.
Why It Matters
Fractyl Health's positive REMAIN-1 study results indicate potential for sustained weight loss benefits from the Revita procedure, enhancing its value and market position in obesity treatment.
Source: MarketBeat
Market Sentiment:
Positive
Quick Summary
Fractyl Health Inc. (NASDAQ:GUTS) announced that its Revita DMR System helped patients retain more GLP-1-induced weight loss in one-year results from the REMAIN-1 study compared to a sham procedure.
Why It Matters
Fractyl Health's positive REMAIN-1 study results indicate potential for Revita DMR to enhance weight loss treatments, boosting investor confidence and highlighting growth prospects.
Source: Benzinga
Market Sentiment:
Positive
Quick Summary
Fractyl Health, Inc. (GUTS) reported on its 1-Year REMAIN-1 data, showing effective weight maintenance after the discontinuation of GLP-1 treatments.
Why It Matters
Durable weight maintenance data post-GLP-1 discontinuation suggests potential for long-term treatment benefits, influencing Fractyl's market position and investor confidence in its product pipeline.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Revita® shows 84% weight loss retention versus 46% with sham after one year. Key milestones include topline data in Q4 2026 and a potential FDA application. Investor webcast scheduled for today at 8:00 a.m. ET.
Why It Matters
The significant weight loss retention data for Revita® suggests strong market potential, influencing investor sentiment and expectations for future FDA approval and company growth.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Participants maintained approximately 78% of their total body weight loss from GLP-1 therapy one year after stopping treatment and undergoing a Revita procedure.
Why It Matters
Retention of 78% weight loss after GLP-1 treatment suggests effective long-term results, potentially increasing demand for related therapies and impacting stock prices of involved biotech companies.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Fractyl Health Appoints Mike Zumdahl as Senior Vice President, Market Access and Commercial Strategy
1 month ago
Quick Summary
Fractyl Health, Inc. (Nasdaq: GUTS) appointed Mike Zumdahl as Senior VP of Market Access and Commercial Strategy, advancing its focus on obesity and type 2 diabetes treatments.
Why It Matters
Fractyl Health's leadership change signals a focus on market access, potentially enhancing its ability to launch products and drive revenue in obesity and diabetes treatments.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About GUTS Stock
What is Fractyl Health Inc.'s (GUTS) stock forecast for 2027?
Based on our analysis of 2 Wall Street analysts, Fractyl Health Inc. (GUTS) has a median price target of $5.10. The highest price target is $8.00 and the lowest is $2.00.
Is GUTS stock a good investment in 2027?
According to current analyst ratings, GUTS has 6 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.85. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for GUTS stock?
Wall Street analysts predict GUTS stock could reach $5.10 in the next 12 months. This represents a 497.0% increase from the current price of $0.85. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Fractyl Health Inc.'s business model?
Fractyl Health Inc. focuses on innovative procedural therapies to treat chronic metabolic conditions, particularly type 2 diabetes, by targeting their root causes. The company generates revenue through its research and clinical trials, aiming to bring new therapies to the market that improve patient outcomes and reduce healthcare costs.
What is the highest forecasted price for GUTS Fractyl Health Inc.?
The highest price target for GUTS is $8.00 from at , which represents a 836.4% increase from the current price of $0.85.
What is the lowest forecasted price for GUTS Fractyl Health Inc.?
The lowest price target for GUTS is $2.00 from at , which represents a 134.1% increase from the current price of $0.85.
What is the overall GUTS consensus from analysts for Fractyl Health Inc.?
The overall analyst consensus for GUTS is bullish. Out of 2 Wall Street analysts, 6 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $5.10.
How accurate are GUTS stock price projections?
Stock price projections, including those for Fractyl Health Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 17, 2026 2:39 AM UTC